Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer
An increased mean platelet volume (MPV) is an early marker of platelet activation. MPV was also shown to be associated with the pathophysiological characteristics of various types of cancer. A previous study demonstrated that MPV was significantly associated with the overall survival (OS) of patient...
Gespeichert in:
Veröffentlicht in: | Molecular and clinical oncology 2015-01, Vol.3 (1), p.197-201 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 201 |
---|---|
container_issue | 1 |
container_start_page | 197 |
container_title | Molecular and clinical oncology |
container_volume | 3 |
creator | KUMAGAI, SHOGO TOKUNO, JUNKO UEDA, YUICHIRO MARUMO, SATOSHI SHOJI, TSUYOSHI NISHIMURA, TAKAFUMI FUKUI, MOTONARI HUANG, CHENG-LONG |
description | An increased mean platelet volume (MPV) is an early marker of platelet activation. MPV was also shown to be associated with the pathophysiological characteristics of various types of cancer. A previous study demonstrated that MPV was significantly associated with the overall survival (OS) of patients with advanced non-small-cell lung cancer (NSCLC). However, there has been no analysis of the prognostic effect of MPV on patients with resected NSCLC. The aim of this study was to evaluate the contribution of MPV to the survival of patients with completely resected NSCLC. We retrospectively analyzed 308 consecutive patients with NSCLC who underwent curative resection at Kitano Hospital. The associations between MPV and clinicopathological factors were assessed. We also evaluated the effect of MPV on survival, using the two-tailed log-rank test and the Cox proportional hazards model. A MPV value of 8.50 fl was considered to be the optimal cut-off value for prognosis. A low MPV was not associated with any other clinicopathological factors. The two-tailed log-rank test demonstrated that patients with a low MPV experienced a shorter disease-free survival (DFS) and overall survival (OS) (P=0.011 and 0.001, respectively), compared to those with a high MPV. The multivariate analysis demonstrated that a low MPV was an independent unfavorable prognostic factor for DFS and OS [hazard ratio (HR)=1.713; 95% confidence interval (CI): 1.070-2.742, P=0.025; and HR=2.835; 95% CI: 1.304-6.163, P=0.009, respectively)]. Therefore, we demonstrated that a low MPV predicted an unfavorable prognosis in patients with NSCLC following curative resection. |
doi_str_mv | 10.3892/mco.2014.436 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4251106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A401095485</galeid><sourcerecordid>A401095485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-8f620c9f5d6a7dc41098a74603902c91bb450acd4f729236e3e9ffa039f1359c3</originalsourceid><addsrcrecordid>eNpdkc9rFDEYhgex2NL25lkCHvTQWfN7JhehFKuFgh70HLKZL2NKJhmTmQX_e7NuXbUhkMD38CQvb9O8JHjDekXfTTZtKCZ8w5l81pxRzFWruFTPj3eBT5vLUh5wXarDVKgXzSkVlaGKnzX2S05jTGXxFhU_Ru-8NdECSg7NGdIM2Sx-B2gCE9EczAIBFrRLYZ0A-YgyFLALDCim2JbJhNBaCAGFNY7otypfNCfOhAKXj-d58-32w9ebT-395493N9f3reWyX9reSYqtcmKQphssJ1j1puMSM4WpVWS7rWGMHbjrqKJMAgPlnKljR5hQlp037w_eed1OMFiISzZBz9lPJv_UyXj9_yT673pMO82pIATLKnj7KMjpxwpl0ZMv-zQmQlqLJj2VkkjCVEVfP0Ef0ppjjaeJYpQLRnv2lxpNAO2jS_Vdu5fqa45rQMF7UamrA2VzKiWDO36ZYL2vWdea9b5mXWuu-Kt_Yx7hP6VW4M0BKLOJgx9SOTJV1GLWYlK36tgv6gOwLg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932453283</pqid></control><display><type>article</type><title>Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>KUMAGAI, SHOGO ; TOKUNO, JUNKO ; UEDA, YUICHIRO ; MARUMO, SATOSHI ; SHOJI, TSUYOSHI ; NISHIMURA, TAKAFUMI ; FUKUI, MOTONARI ; HUANG, CHENG-LONG</creator><creatorcontrib>KUMAGAI, SHOGO ; TOKUNO, JUNKO ; UEDA, YUICHIRO ; MARUMO, SATOSHI ; SHOJI, TSUYOSHI ; NISHIMURA, TAKAFUMI ; FUKUI, MOTONARI ; HUANG, CHENG-LONG</creatorcontrib><description>An increased mean platelet volume (MPV) is an early marker of platelet activation. MPV was also shown to be associated with the pathophysiological characteristics of various types of cancer. A previous study demonstrated that MPV was significantly associated with the overall survival (OS) of patients with advanced non-small-cell lung cancer (NSCLC). However, there has been no analysis of the prognostic effect of MPV on patients with resected NSCLC. The aim of this study was to evaluate the contribution of MPV to the survival of patients with completely resected NSCLC. We retrospectively analyzed 308 consecutive patients with NSCLC who underwent curative resection at Kitano Hospital. The associations between MPV and clinicopathological factors were assessed. We also evaluated the effect of MPV on survival, using the two-tailed log-rank test and the Cox proportional hazards model. A MPV value of 8.50 fl was considered to be the optimal cut-off value for prognosis. A low MPV was not associated with any other clinicopathological factors. The two-tailed log-rank test demonstrated that patients with a low MPV experienced a shorter disease-free survival (DFS) and overall survival (OS) (P=0.011 and 0.001, respectively), compared to those with a high MPV. The multivariate analysis demonstrated that a low MPV was an independent unfavorable prognostic factor for DFS and OS [hazard ratio (HR)=1.713; 95% confidence interval (CI): 1.070-2.742, P=0.025; and HR=2.835; 95% CI: 1.304-6.163, P=0.009, respectively)]. Therefore, we demonstrated that a low MPV predicted an unfavorable prognosis in patients with NSCLC following curative resection.</description><identifier>ISSN: 2049-9450</identifier><identifier>EISSN: 2049-9469</identifier><identifier>DOI: 10.3892/mco.2014.436</identifier><identifier>PMID: 25469294</identifier><language>eng</language><publisher>England: D.A. Spandidos</publisher><subject>Age ; Analysis ; Blood ; Blood platelets ; Cancer therapies ; Chemotherapy ; Confidence intervals ; curative resection ; Diagnosis ; Disease ; disease-free survival ; Gender ; Hematology ; Histology ; Hospitals ; Lung cancer ; Lung cancer, Non-small cell ; Lymphatic system ; mean platelet volume ; Measurement ; Medical prognosis ; Medical research ; Multivariate analysis ; Oncology ; overall survival ; Patients ; Physiological aspects ; prognosis ; Studies ; Surgery ; Survival analysis</subject><ispartof>Molecular and clinical oncology, 2015-01, Vol.3 (1), p.197-201</ispartof><rights>Copyright © 2015, Spandidos Publications</rights><rights>COPYRIGHT 2015 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2015</rights><rights>Copyright © 2015, Spandidos Publications 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-8f620c9f5d6a7dc41098a74603902c91bb450acd4f729236e3e9ffa039f1359c3</citedby><cites>FETCH-LOGICAL-c468t-8f620c9f5d6a7dc41098a74603902c91bb450acd4f729236e3e9ffa039f1359c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251106/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251106/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,5556,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25469294$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KUMAGAI, SHOGO</creatorcontrib><creatorcontrib>TOKUNO, JUNKO</creatorcontrib><creatorcontrib>UEDA, YUICHIRO</creatorcontrib><creatorcontrib>MARUMO, SATOSHI</creatorcontrib><creatorcontrib>SHOJI, TSUYOSHI</creatorcontrib><creatorcontrib>NISHIMURA, TAKAFUMI</creatorcontrib><creatorcontrib>FUKUI, MOTONARI</creatorcontrib><creatorcontrib>HUANG, CHENG-LONG</creatorcontrib><title>Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer</title><title>Molecular and clinical oncology</title><addtitle>Mol Clin Oncol</addtitle><description>An increased mean platelet volume (MPV) is an early marker of platelet activation. MPV was also shown to be associated with the pathophysiological characteristics of various types of cancer. A previous study demonstrated that MPV was significantly associated with the overall survival (OS) of patients with advanced non-small-cell lung cancer (NSCLC). However, there has been no analysis of the prognostic effect of MPV on patients with resected NSCLC. The aim of this study was to evaluate the contribution of MPV to the survival of patients with completely resected NSCLC. We retrospectively analyzed 308 consecutive patients with NSCLC who underwent curative resection at Kitano Hospital. The associations between MPV and clinicopathological factors were assessed. We also evaluated the effect of MPV on survival, using the two-tailed log-rank test and the Cox proportional hazards model. A MPV value of 8.50 fl was considered to be the optimal cut-off value for prognosis. A low MPV was not associated with any other clinicopathological factors. The two-tailed log-rank test demonstrated that patients with a low MPV experienced a shorter disease-free survival (DFS) and overall survival (OS) (P=0.011 and 0.001, respectively), compared to those with a high MPV. The multivariate analysis demonstrated that a low MPV was an independent unfavorable prognostic factor for DFS and OS [hazard ratio (HR)=1.713; 95% confidence interval (CI): 1.070-2.742, P=0.025; and HR=2.835; 95% CI: 1.304-6.163, P=0.009, respectively)]. Therefore, we demonstrated that a low MPV predicted an unfavorable prognosis in patients with NSCLC following curative resection.</description><subject>Age</subject><subject>Analysis</subject><subject>Blood</subject><subject>Blood platelets</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Confidence intervals</subject><subject>curative resection</subject><subject>Diagnosis</subject><subject>Disease</subject><subject>disease-free survival</subject><subject>Gender</subject><subject>Hematology</subject><subject>Histology</subject><subject>Hospitals</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Lymphatic system</subject><subject>mean platelet volume</subject><subject>Measurement</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>overall survival</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>prognosis</subject><subject>Studies</subject><subject>Surgery</subject><subject>Survival analysis</subject><issn>2049-9450</issn><issn>2049-9469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkc9rFDEYhgex2NL25lkCHvTQWfN7JhehFKuFgh70HLKZL2NKJhmTmQX_e7NuXbUhkMD38CQvb9O8JHjDekXfTTZtKCZ8w5l81pxRzFWruFTPj3eBT5vLUh5wXarDVKgXzSkVlaGKnzX2S05jTGXxFhU_Ru-8NdECSg7NGdIM2Sx-B2gCE9EczAIBFrRLYZ0A-YgyFLALDCim2JbJhNBaCAGFNY7otypfNCfOhAKXj-d58-32w9ebT-395493N9f3reWyX9reSYqtcmKQphssJ1j1puMSM4WpVWS7rWGMHbjrqKJMAgPlnKljR5hQlp037w_eed1OMFiISzZBz9lPJv_UyXj9_yT673pMO82pIATLKnj7KMjpxwpl0ZMv-zQmQlqLJj2VkkjCVEVfP0Ef0ppjjaeJYpQLRnv2lxpNAO2jS_Vdu5fqa45rQMF7UamrA2VzKiWDO36ZYL2vWdea9b5mXWuu-Kt_Yx7hP6VW4M0BKLOJgx9SOTJV1GLWYlK36tgv6gOwLg</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>KUMAGAI, SHOGO</creator><creator>TOKUNO, JUNKO</creator><creator>UEDA, YUICHIRO</creator><creator>MARUMO, SATOSHI</creator><creator>SHOJI, TSUYOSHI</creator><creator>NISHIMURA, TAKAFUMI</creator><creator>FUKUI, MOTONARI</creator><creator>HUANG, CHENG-LONG</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer</title><author>KUMAGAI, SHOGO ; TOKUNO, JUNKO ; UEDA, YUICHIRO ; MARUMO, SATOSHI ; SHOJI, TSUYOSHI ; NISHIMURA, TAKAFUMI ; FUKUI, MOTONARI ; HUANG, CHENG-LONG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-8f620c9f5d6a7dc41098a74603902c91bb450acd4f729236e3e9ffa039f1359c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Age</topic><topic>Analysis</topic><topic>Blood</topic><topic>Blood platelets</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Confidence intervals</topic><topic>curative resection</topic><topic>Diagnosis</topic><topic>Disease</topic><topic>disease-free survival</topic><topic>Gender</topic><topic>Hematology</topic><topic>Histology</topic><topic>Hospitals</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Lymphatic system</topic><topic>mean platelet volume</topic><topic>Measurement</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>overall survival</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>prognosis</topic><topic>Studies</topic><topic>Surgery</topic><topic>Survival analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KUMAGAI, SHOGO</creatorcontrib><creatorcontrib>TOKUNO, JUNKO</creatorcontrib><creatorcontrib>UEDA, YUICHIRO</creatorcontrib><creatorcontrib>MARUMO, SATOSHI</creatorcontrib><creatorcontrib>SHOJI, TSUYOSHI</creatorcontrib><creatorcontrib>NISHIMURA, TAKAFUMI</creatorcontrib><creatorcontrib>FUKUI, MOTONARI</creatorcontrib><creatorcontrib>HUANG, CHENG-LONG</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KUMAGAI, SHOGO</au><au>TOKUNO, JUNKO</au><au>UEDA, YUICHIRO</au><au>MARUMO, SATOSHI</au><au>SHOJI, TSUYOSHI</au><au>NISHIMURA, TAKAFUMI</au><au>FUKUI, MOTONARI</au><au>HUANG, CHENG-LONG</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer</atitle><jtitle>Molecular and clinical oncology</jtitle><addtitle>Mol Clin Oncol</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>3</volume><issue>1</issue><spage>197</spage><epage>201</epage><pages>197-201</pages><issn>2049-9450</issn><eissn>2049-9469</eissn><abstract>An increased mean platelet volume (MPV) is an early marker of platelet activation. MPV was also shown to be associated with the pathophysiological characteristics of various types of cancer. A previous study demonstrated that MPV was significantly associated with the overall survival (OS) of patients with advanced non-small-cell lung cancer (NSCLC). However, there has been no analysis of the prognostic effect of MPV on patients with resected NSCLC. The aim of this study was to evaluate the contribution of MPV to the survival of patients with completely resected NSCLC. We retrospectively analyzed 308 consecutive patients with NSCLC who underwent curative resection at Kitano Hospital. The associations between MPV and clinicopathological factors were assessed. We also evaluated the effect of MPV on survival, using the two-tailed log-rank test and the Cox proportional hazards model. A MPV value of 8.50 fl was considered to be the optimal cut-off value for prognosis. A low MPV was not associated with any other clinicopathological factors. The two-tailed log-rank test demonstrated that patients with a low MPV experienced a shorter disease-free survival (DFS) and overall survival (OS) (P=0.011 and 0.001, respectively), compared to those with a high MPV. The multivariate analysis demonstrated that a low MPV was an independent unfavorable prognostic factor for DFS and OS [hazard ratio (HR)=1.713; 95% confidence interval (CI): 1.070-2.742, P=0.025; and HR=2.835; 95% CI: 1.304-6.163, P=0.009, respectively)]. Therefore, we demonstrated that a low MPV predicted an unfavorable prognosis in patients with NSCLC following curative resection.</abstract><cop>England</cop><pub>D.A. Spandidos</pub><pmid>25469294</pmid><doi>10.3892/mco.2014.436</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2049-9450 |
ispartof | Molecular and clinical oncology, 2015-01, Vol.3 (1), p.197-201 |
issn | 2049-9450 2049-9469 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4251106 |
source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Age Analysis Blood Blood platelets Cancer therapies Chemotherapy Confidence intervals curative resection Diagnosis Disease disease-free survival Gender Hematology Histology Hospitals Lung cancer Lung cancer, Non-small cell Lymphatic system mean platelet volume Measurement Medical prognosis Medical research Multivariate analysis Oncology overall survival Patients Physiological aspects prognosis Studies Surgery Survival analysis |
title | Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T16%3A50%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20preoperative%20mean%20platelet%20volume%20in%20resected%20non-small-cell%20lung%20cancer&rft.jtitle=Molecular%20and%20clinical%20oncology&rft.au=KUMAGAI,%20SHOGO&rft.date=2015-01-01&rft.volume=3&rft.issue=1&rft.spage=197&rft.epage=201&rft.pages=197-201&rft.issn=2049-9450&rft.eissn=2049-9469&rft_id=info:doi/10.3892/mco.2014.436&rft_dat=%3Cgale_pubme%3EA401095485%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932453283&rft_id=info:pmid/25469294&rft_galeid=A401095485&rfr_iscdi=true |